Purpose Trials combining irinotecan/docetaxel and irinotecan/gemcitabine in second-line
treatment of non–small-cell lung cancer (NSCLC) have yielded promising results …

Purpose Radioresistance is highly correlated with radiotherapy failure in clinical cancer
treatment. In the current study, we sought to examine the efficacy of Celecoxib and Afatinib …

The forkhead transcription factor hepatocyte nuclear factor 3β (HNF3β) is essential in foregut
development and the regulation of lung-specific genes. HNF3β expression leads to growth …

Epidermal growth factor receptor (EGFR) activation is a major cause of metastasis in many
cancers, such as head and neck squamous cell carcinoma (HNSCC). However, whether the …

Agents can enter clinical development for cancer prevention either initially or after previous
development for a different indication, such as arthritis, with both approaches consuming …

Lung cancer is one of the most deadly diseases worldwide. The current first-line therapies
include chemotherapy using epidermal growth factor receptor tyrosine kinase inhibitors and …

Abstract Purpose: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …

Purpose In non–small-cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …

Inflammation is an important contributor to lung tumor development and progression. In
addition, inflammatory signaling may promote epithelial to mesenchymal transition …

Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …